OncoMatch/Clinical Trials/NCT06516133
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
Is NCT06516133 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Chemotherapy and Chemotherapy for nasopharyngeal carcinoma.
Treatment: Chemotherapy · Chemotherapy — In this multicenter, prospective, randomized, controlled, non-inferiority Phase III clinical trial, treatment-naïve patients with nasopharyngeal carcinoma (NPC) without metastasis will be enrolled for curative radiotherapy. The participants will be randomly assigned to two groups. The experimental group will receive online adaptive radiotherapy (ART) during the radiotherapy process, with a smaller PTV margin, while the control group will use original treatment plan during full-course radiotherapy, with a PTV margin of 3 mm. The study aims to compare the survival, adverse events, and quality of survival between the two groups, with the primary endpoint being the locoregional recurrence-free survival rate. The main objective is to determine the role of online ART in nasopharyngeal carcinoma, elucidating its potential to alleviate radiation toxicity in patients while ensuring treatment efficacy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Previous radical radiotherapy for nasopharyngeal cancer
Cannot have received: chemotherapy
Primary and neck metastatic lesions treated with chemotherapy or surgery
Cannot have received: surgery
Primary and neck metastatic lesions treated with chemotherapy or surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify